Log in
Enquire now
‌

NUBAD, LLC STTR Phase I Award, December 2017

A STTR Phase I contract was awarded to NUBAD, LLC in December, 2017 for $670,352.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.

OverviewStructured DataIssuesContributors

Contents

sbir.gov/node/1565269
Is a
SBIR/STTR Awards
SBIR/STTR Awards

SBIR/STTR Award attributes

SBIR/STTR Award Recipient
‌
NUBAD, LLC
0
Government Agency
0
Government Branch
National Institutes of Health
National Institutes of Health
0
Award Type
STTR0
Contract Number (US Government)
1R41DC016257-01A10
Award Phase
Phase I0
Award Amount (USD)
670,3520
Date Awarded
December 1, 2017
0
End Date
November 30, 2020
0
Abstract

PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComplexes between ribosomal components will be exploited as targets for small molecule drug libraries thatinactivate the ribosomestopping bacterial protein synthesis and causing bacterial death while reducing toxicityThis work addresses an important health issueantibiotic ototoxicityand presents creative steps towards a novel solution to this problemThe work proposed herea multidisciplinary effort encompassing antibacterial screening and ototoxicity studies using zebrafish and guinea pig modelsdescribes the development of novel aminosugar rRNA binders as non toxic antibacterial therapeuticsThe success of the proposed work would be a significant addition to currently available approaches in antibacterial therapyWe propose using novel aminoglycoside modifications and patented NUBAD assays to identify conjugates that show reduced toxicitiesopening possibilities for developing RNA targeted therapeutics with reduced toxicity PROJECT NARRATIVE The proposed project presents a strategy for developing novel aminoglycoside therapeutics with new heterocyclic rRNA recognition motifs to reduce ototoxicitiesAntimicrobial resistance occurs when microorganismsoften infectious bacteriavirusesand certain parasitesare no longer sensitive to drugs that were previously used to treat themthis is of global concern because it hampers our ability to control infectious disease and increases the costs of health careIn order to combat this world wide probleminnovative strategies for antibiotic drug design must be implementedThe proposed research describes a strategy for improving the therapeutic index of aminoglycosides by designing novel structures that lower their ototoxicity and evade common resistance pathways!

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like NUBAD, LLC STTR Phase I Award, December 2017

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.